[Presentation] Improving the Staging and Diagnosis of Patients With Stage III/IV Non-Small Cell Lung Cancer: Findings for Pathology and Pulmonary Medicine From a National Quality Survey

Presented at the CAP 2020 Virtual Meeting, October 10-13, 2020.

Authors

S. Michelle Shiller, DO;¹ David Feller-Kopman, MD, FCCP;² Nabil Chehab, PhD, MBA;³ Leigh Boehmer, PharmD, BCOP.⁴

¹Department of Molecular Medicine and Pathology, Baylor University Medical Center/PathGroup-PBM, Dallas, Texas; ²Department of Pulmonary and Critical Care Medicine, The Johns Hopkins Hospital, Baltimore, Maryland; ³ US Oncology Medical Affairs, AstraZeneca, Gaithersburg, Maryland; ⁴Department of Education, Association of Community Cancer Centers, Rockville, Maryland.

Background

Systematic staging and guideline-consistent biomarker testing are critical to the evaluation, treatment, and prognosis of stageIII/IV non–small cell lung cancer (NSCLC). Pathologists and pulmonologists were among the key respondents to a National Quality Survey to identify barriers to ideal NSCLC care delivery that could inform process improvements.

Infographic

Download Infographic 

 

Video Summary

 

ACCC Buzz Blog Post

ASCO Abstract: What Defines Quality Lung Cancer Care?
June 12, 2020